<div id="readability-page-1">07:40 AM EST, 12/04/2025 (MT Newswires) -- uniQure (QURE) said Thursday that it will &#34;urgently&#34; seek a follow-up&#34; meeting with the US Food and Drug Administration after the regulator said phase 1/2 studies of AMT-130 data are now unlikely to support a Biologics License Application submission.AMT-130 is an investigational gene therapy intended to treat patients with Huntington's disease, the company said.uniQure said it is evaluating the feedback and is looking to meet with the FDA in Q1.Shares of uniQure were down 19% in recent Thursday premarket activity. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

QURE

uniQure 计划在被告知 AMT-130 的 1/2 期研究数据不太可能支持生物制品许可申请后，紧急与美国 FDA 会面。AMT-130 是一种用于亨廷顿舞蹈症的基因疗法。该公司旨在于第一季度与 FDA 会面。uniQure 的股票在盘前交易中下跌了 19%

Uniqure 在被告知数据不支持生物制品许可申请（BLA）提交后，寻求与美国食品药品监督管理局（FDA）的后续会议